Discover

March 18 Is Kick Butts Day…Two Ways to Fight Lung Cancer

On International Women’s Day: Q&A with CSO Dena Marrinucci

This Week at ASCO GU 2015: Detecting PD-L1 in Metastatic Bladder Cancer

This Week at ASCO GU 2015: New Potential Diagnostic Biomarker for Neuroendocrine Prostate Cancer

This Week at ASCO GU 2015: Predicting Therapy Response in Metastatic Castration-Resistant Prostate Cancer

Detecting PD-L1 in Circulating Tumor Cells Could Improve Immunotherapies

Liquid biopsy, or blood sample tests, under development by Epic Sciences can generate real time information on the presence of PD-L1 protein in tumors by analyzing circulating tumor cells (CTCs). Identifying patients with PD-L1-expressing tumor cells is essential for the new generation of cancer immunotherapies rapidly progressing in clinical trials.

FAQs: Circulating Tumor Cells (CTCs)

Circulating tumor cells (CTCs) are cells that have broken away from a primary tumor and enter the bloodstream. The mere presence of one or more CTC type described above can give us clues about a cancer’s origin, metastatic risk, and prognosis. From a liquid biopsy, Epic’s no cell left behind™ technology can help match patients to therapies for personalized medicine.

Lung Cancer Awareness Month: What You Should Know About Metastasis

Metastatic cancer is a cancer that has spread through the bloodstream or lymphatic system from the part of the body where it started to other parts of the body. Circulating tumor cells are pivotal to understanding the biology of metastasis and promise potential as a biomarker to, noninvasively through a liquid biopsy, evaluate tumor progression and response to treatment, especially in lung cancer where tissue biopsies are difficult to obtain.

Patient selection & predictive medicine from a tube of blood? | GU14 AACR-PCF

Real-time tumor biopsies | GU14 AACR-PCF

Highly sensitive, single cell analysis | GU14 AACR-PCF

The discovery and relevance of novel CTC subtypes | GU14 AACR-PCF

Research presentations at GU14 and AACR-PCF in January 2014

In January, we and our collaborators presented at GU14 and AACR-PCF. The next four blog posts provide an overview of data presented at these two conferences.

Prospective Clinical Research Study Shows New Assay Can Detect Circulating Endothelial Cells in Heart Attack Patients

There is no method in today’s clinical practice to reliably predict an imminent heart attack. A test that could identify individuals at greatest risk for an imminent heart attack would be a much-needed predictive tool.